Merck KGaA

An imaginary winners podium is modelled and rendered
Biotech

Merck KGaA tumor trial hits goal, teeing up Daiichi, Ono rivalry

The TGCT hit its primary endpoint, teeing up an option decision that could establish Merck’s as a global rival to Daiichi and Ono in the indication.
Nick Paul Taylor Nov 12, 2024 4:46am
dart board miss failure

Merck KGaA drops xevinapant with ph. 3 trial headed for failure

Jun 25, 2024 8:50am
AI artificial intelligence drug development computational biology machine learning

Merck KGaA taps AI-focused biotech for new ADC pact worth $376M

Jun 4, 2024 9:45am
A graphic representation of a DNA sequence

Merck KGaA rolls out ‘all-in-one’ CHO genetic stability assay

Apr 18, 2024 4:05pm
Focus magnify target strategy

Merck KGaA signs $1.4B biobuck ADC deal with Caris

Apr 4, 2024 8:25am
end of the road road block shut down closed blocked

Merck KGaA drops evobrutinib in wake of double phase 3 fail

Mar 7, 2024 9:54am